Tribune Therapeutics
Manufacturing · Sweden · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Engelbrektsplan 1, Stockholm, Stockholm,...Website
www.tribunetx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Tribune Therapeutics
Tribune Therapeutics is a preclinical biopharmaceutical company focused on developing innovative medicines for a variety of fibrotic diseases. Founded in 2020, the company leverages insights from nature to target the underlying mechanisms of fibrosis through its promising pipeline, including its lead candidate TRX-44. Their approach aims to interrupt key pathways that lead to scar formation and organ failure caused by fibrosis. The company's intended clients are patients affected by fibrotic diseases across different tissues and causes.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tribune Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Tribune Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Tribune Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check out if Tribune Therapeutics is spiking on competitors!
Product Launch: Get notified when Tribune Therapeutics launches new products
Earning: See what the market has to say on Tribune Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Tribune Therapeutics has new funding data
Tribune Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Tribune Therapeutics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Tribune Therapeutics
Compare insights from companies similar to Tribune Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Tribune Therapeutics
<$5M
1-10
Private
$39.8M
2020
N/A
Company Profile Activity
Activity Insights
Tribune Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Tribune Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Tribune Therapeutics.
Tribune Therapeutics financials insights
Gather financial insights about Tribune Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Angel/Seed
$15M
Series A
$24.8M
Tribune Therapeutics Tech Stack
A closer look at the technologies used by Tribune Therapeutics
See more technologies
Tribune Therapeutics News & Media
Novo Holdings participates in €23 million Series A for Tribune Therapeutics to advance next-generation anti-fibrotic therapies
Investment addresses the need for disease-modifying therapies targeting the root causes of fibrosis Funding will support the advancement of CCN family inhibitor TRX-44 into clinical trials for treatment of fibrotic conditions including idiopathic pulmonary fibrosis (IPF) Novo Holdings and...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Tribune Therapeutics
Sign Up For FreeTo access detailed company insights
Tribune Therapeutics is a preclinical biopharmaceutical company focused on developing innovative medicines for a variety of fibrotic diseases. Founded in 2020, the company leverages insights from nature to target the underlying mechanisms of fibrosis through its promising pipeline, including its lead candidate TRX-44. Their approach aims to interru... Read More
